Cancer Capital (CNCL) 10-Q2011 Q1 Quarterly report

Filed: 6 May 11, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: accrued, addressed, administrative, April, attached, Bierwolf, Board, Certifying, Chisholm, copy, dismissed, exhibit, expense, February, firm, funding, increased, independent, issuer, letter, LLC, long, minimal, Morrill, net, Nilson, ongoing, Oversight, payable, PCAOB, prior, profitability, quality, registered, representative, requested, revocation, revoked, source, sufficient, suitable, term, violation

Removed: acquisition, advantage, analyzing, Capitol, consummating, identified, incur, investigate, investigating, limited, person, preliminary, pursue, reached, seek, warranted

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

CNCL similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

[cancer10qletter001.jpg]

May 6, 2011

Office of the Chief Accountant

Securities and Exchange Commission

450 West Fifth Street N.W.

Washington DC 20549

Ladies and Gentlemen,

We have read the statements about our firm included under Item 5 “Other Information” in the Form 10-Q for the quarter ended March 31, 2011 of Cancer Capital Corp. and are in agreement with the statements contained therein as they pertain to our firm.

Sincerely,

/s/ Chisholm, Bierwolf, Nilson & Morrill

Chisholm, Bierwolf, Nilson & Morrill

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.